Status:
COMPLETED
Effect of 5 Years of GH Replacement on Atherosclerosis
Lead Sponsor:
Federico II University
Conditions:
Hypopituitarism
Pituitary Tumors
Eligibility:
MALE
18-50 years
Brief Summary
Adult patients with hypopituitarism under adequate conventional hormone replacement therapy have reduced life expectancy due to excess vascular events (1-4). Deficiency in GH secretion (GHD) is likely...
Detailed Description
This is an observational,5-yr prospective, controlled study. At study entry, all subjects underwent serum assay of IGF-I, systolic and diastolic blood pressure (SBP, DBP) measurement, total-, and HDL-...
Eligibility Criteria
Inclusion
- male gender
- age \<50 yrs to limit the effect of aging;
- body mass index \<30 Kg/m2;
- no familial or personal history of cardiovascular diseases;
- no concomitant treatment with drugs known to interfere with glucose or lipid metabolism or to influence blood pressure at the time of study entry;
- no previous GH treatment
Exclusion
- female gender
- age \>50 yrs;
- body mass index ≥30;
- familial or personal history of cardiovascular diseases;
- previous and present treatments with drugs known to interfere with glucose or lipid metabolism or to influence blood pressure;
- previous GH treatment in adult age
- GHD of childhood onset
- GHD due to previous Cushing's disease
Key Trial Info
Start Date :
January 1 1996
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00462475
Start Date
January 1 1996
End Date
December 1 2006
Last Update
October 16 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Molecular and Clinical Endocirnology and Oncology University Federico II of Naples
Naples, Italy, 80131